Related Experiment Video

Updated: Sep 25, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular

Samuel Chackalamannil1

  • 1Chemical Research, Schering-Plough Research Institute, Galloping Hill Road, Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com

Current Topics in Medicinal Chemistry
|May 29, 2003
PubMed

Insights

Thrombin receptor (PAR-1) antagonists offer a novel therapeutic strategy for cardiovascular diseases. These agents show potential for reduced bleeding risk compared to existing treatments, with demonstrated antithrombotic and anti-restenosis effects.

Area of Science:

  • Cardiovascular Pharmacology
  • Thrombosis Research
  • Drug Development

Background:

  • Thrombin receptor (PAR-1) plays a key role in cardiovascular pathophysiology.
  • Current antithrombotic therapies carry a significant risk of bleeding.
  • PAR-1 antagonists offer a targeted approach to inhibit thrombin's cellular effects.

Purpose of the Study:

  • To explore the therapeutic potential of PAR-1 inhibition in cardiovascular disorders.
  • To evaluate the efficacy and safety profile of PAR-1 antagonists.
  • To investigate the antithrombotic and anti-restenosis properties of PAR-1 antagonists.

Main Methods:

  • Review of existing literature on PAR-1 antagonists.
  • Preclinical studies involving PAR-1 antibodies in baboon thrombosis models.
  • Preclinical studies involving PAR-1 antagonists in rat restenosis models.

Main Results:

  • Several potent peptide and non-peptide PAR-1 antagonists inhibiting platelet aggregation have been identified.
  • A PAR-1 antibody demonstrated antithrombotic effects in vivo.
  • A PAR-1 antagonist exhibited antirestenosis properties in vivo.

Conclusions:

  • PAR-1 antagonists represent a promising therapeutic avenue for cardiovascular diseases like stroke and myocardial infarction.
  • Targeting PAR-1 offers a potential for reduced bleeding complications compared to conventional treatments.
  • Further clinical investigation of PAR-1 antagonists is warranted.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G Protein-coupled Receptors01:27

G Protein-coupled Receptors

G-protein-coupled receptors are ligand-binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that traverses the cell membrane seven times, creating intracellular and extracellular loops. The extracellular loops create a ligand-specific pocket which binds to neurotransmitters or hormones. The intracellular loops hold onto the G-protein.The G-protein, or guanine nucleotide-binding protein, is a large heterotrimeric complex. Its three subunits...